ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
GDF15 Ameliorates Deoxynivalenol-Induced Anemia by Resolving Ribosomal Stress-Mediated Erythropoietic Arrest.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating Single-Cell, Bulk, and Spatial Transcriptomics Unveils a Novel Ribosome Biogenesis-Related Prognostic Model and DefinesInternational journal of molecular sciences · 2026Article
- GDF15 Ameliorates Deoxynivalenol-Induced Anemia by Resolving Ribosomal Stress-Mediated Erythropoietic Arrest.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Deoxynivalenol (DON) is a prevalent trichothecene mycotoxin that contaminates global food supplies, posing significant health risks; however, targeted therapies against DON are scarce. Although DON-induced anemia is well-documented, the underlying mechanisms remain unclear. In this study, the effects of DON on erythropoiesis are examined in detail using complementary murine models and human primary erythroid cultures. DON impaired erythropoiesis by disrupting hematopoietic homeostasis as well as erythroid commitment and differentiation via ribosomal stress-mediated cell cycle arrest. Multi-omics analyses revealed that the effects of DON are attributed to ribosomal dysfunction, which selectively disrupted protein synthesis without altering mRNA expression. Mechanistically, DON downregulated translation of growth differentiation factor 15 (GDF15) along with decreases in β-catenin, Myc, and p21. Importantly, GDF15 supplementation rescued DON-induced erythropoietic defects in vitro and in vivo, restored levels of β-catenin, Myc, and p21, and cell cycle progression, indicating DON inhibits erythropoiesis via the GDF15-β-catenin-Myc-p21 axis. These findings elucidate the pathogenesis of DON-induced anemia and identify GDF15 as a novel therapeutic target against mycotoxin poisoning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.